Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10189883 Therapeutic uses of modified FGF-21 polypeptides

Patent 10189883 was granted and assigned to Bristol-Myers Squibb on January, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

All edits

Edits on 30 May, 2024
"update inverses"
Golden AI profile picture
Golden AI
edited on 30 May, 2024
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
‌
US Patent 11993637 Modified FGF-21 polypeptides with non-naturally encoded amino acids
0
Edits on 8 Dec, 2023
"Add patent abstract"
Golden AI profile picture
Golden AI
edited on 8 Dec, 2023
Edits made to:
Article (+373 characters)
Article

Patent abstract

Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

Edits on 10 May, 2023
"update inverses"
Golden AI profile picture
Golden AI
edited on 10 May, 2023
Edits on 26 Apr, 2023
"update citations for inverse infoboxes"
Golden AI profile picture
Golden AI
edited on 26 Apr, 2023
Edits on 5 Apr, 2023
"update citations for inverse infoboxes"
Golden AI profile picture
Golden AI
edited on 5 Apr, 2023
Edits on 22 Mar, 2023
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 22 Mar, 2023
Edits on 26 Sep, 2022
"update citations for inverse infoboxes"
Golden AI profile picture
Golden AI
edited on 26 Sep, 2022
Edits on 25 Sep, 2022
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 25 Sep, 2022
Edits on 31 Aug, 2022
"update inverses"
Golden AI profile picture
Golden AI
edited on 31 Aug, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
‌
US Patent 11427623 Methods of treatment using mutant FGF-21 peptide conjugates
Edits on 16 Feb, 2022
"update inverses"
Golden AI profile picture
Golden AI
edited on 16 Feb, 2022
Edits on 28 Jan, 2022
"update inverses"
Golden AI profile picture
Golden AI
edited on 28 Jan, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
‌
US Patent 10407479 Mutant FGF-21 peptide pegylated conjugates and uses thereof
Edits on 24 Jan, 2022
"Created via: Entity Importer"
Golden AI profile picture
Golden AI
created this topic on 24 Jan, 2022
Edits made to:
Infobox (+9 properties)
‌

 US Patent 10189883 Therapeutic uses of modified FGF-21 polypeptides

Infobox
Is a
Patent
Patent
Patent applicant
Bristol-Myers Squibb
Bristol-Myers Squibb
Current assignee
Bristol-Myers Squibb
Bristol-Myers Squibb
Patent jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent number
10189883
Date of patent
January 29, 2019
Patent application number
15460917
Date Filed
March 16, 2017
Patent primary examiner
‌
Christine J. Saoud

Find more entities like US Patent 10189883 Therapeutic uses of modified FGF-21 polypeptides

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo